Brief by Shorts91 Newsdesk / 02:57pm on 13 Sep 2024,Friday Health & Wellness
The World Health Organization (WHO) has prequalified the MVA-BN vaccine as the first mpox vaccine, enhancing access to vital immunization against the disease. Approved for individuals over 18, the vaccine is administered in two doses, four weeks apart. It can be stored at 2-8°C for up to eight weeks. The WHO emphasizes urgent procurement and distribution to tackle ongoing outbreaks, particularly in Africa. While the vaccine is not licensed for those under 18, it may be used "off-label" in high-risk outbreak settings. Data shows the vaccine's effectiveness at 76% for single-dose and 82% for the two-dose regimen.
